These estimates are produced using the following method:
Step 1: Take prevalence rates measured across Europe by the Alzheimer Europe / Eurodem consortium โ large, well-validated studies across multiple European countries.
Step 2: Apply those European rates to Ireland's CSO Census 2022 population data โ broken down by age group and county.
Step 3: The result is a credible estimate โ but it assumes Ireland's dementia rates mirror European averages, which may not be exactly true. The peer-reviewed Irish study (Cahill et al. 2019, Irish Journal of Psychological Medicine) found the total could range from 39,272 to 65,266 depending on which European rates are applied, and explicitly states: "Without a national prevalence study it is not possible to be precise about the estimates of the number of people with dementia in Ireland."
What IS measured directly in Ireland: The annual new cases figure (11,000 โ Alzheimer Society of Ireland), the economic cost study (Connolly et al. 2014, NUI Galway), and the 2050 projection (Alzheimer Europe 2020, cited by ASI). These rest on a firmer evidential base.
The case for a national Irish prevalence survey has never been stronger โ and this dashboard is a direct illustration of why one is needed.
Alzheimer's disease accounts for approximately 60โ70% of all dementia cases. Vascular dementia, Lewy body dementia, and frontotemporal dementia make up the remainder. Learn more at Alzheimer Europe โ
Age-specific rates are drawn from the Alzheimer Europe / Eurodem consortium methodology. Applied to Irish census population data (CSO 2022). No Ireland-specific age-stratified study exists.
These projections assume no major treatment breakthroughs. Alzheimer Europe (2020) projects 141,200 cases in Ireland by 2050 โ this is the most widely cited official figure. The ASI states cases will exceed 150,000 by 2045. Both use different base years and methodologies. See the Global Scenarios section for how treatments could change this outlook.
Note: the โฌ1.69bn figure is from 2010 data. With today's larger caseload and higher care costs, the true 2025 figure is substantially higher โ a 2024 update has not been published for Ireland specifically. The updated Irish estimate is approximately โฌ1.9 billion (Connolly et al. in ScienceDirect 2024).
The higher proportion of women largely reflects longer life expectancy, as dementia risk rises steeply with age. Women are also disproportionately represented as unpaid family carers โ the Lancet 2024 Commission specifically notes gender as a social determinant of dementia care burden. Lancet 2024 โ
Important limitation: There is no national dementia prevalence survey in Ireland. Cahill et al. (Irish Journal of Psychological Medicine, 2019) state explicitly: "Without a national prevalence study it is not possible to be precise about the estimates of the number of people with dementia in Ireland." County figures here are generated by applying the national average rate to CSO 2022 population data. They are planning estimates only โ not survey results.
Primary source: Livingston G et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572โ628. DOI: 10.1016/S0140-6736(24)01296-0 ยท Read full paper (open access) โ
This calculator is an illustrative population-level modelling tool only. It is not a validated clinical instrument and should not be used for individual patient risk assessment. PAF values and relative risks are from Lancet Commission 2024 global data โ they may not perfectly reflect the Irish population. Maximum modelled reduction is capped at 45% (the Lancet 2024 global PAF total).
Estimated cases preventable in Ireland
PAF methodology โ illustrative model only
Global context: The WHO and Alzheimer's Disease International estimate approximately 55 million people worldwide live with dementia today. Alzheimer Europe (2025) reports 12.1 million in Europe, projected to reach 19.9 million by 2050. Sources: Alzheimer Europe prevalence โ
For decades, dementia had no disease-modifying treatments โ only drugs that managed symptoms. That has now changed. The first medications that can genuinely slow Alzheimer's progression were approved in the US in 2023 and 2024. These drugs are not yet approved in Europe (EMA review ongoing as of early 2026). This is a historic shift, but these are not cures. Browse active trials โ
For Ireland specifically: Neither lecanemab nor donanemab are available through the HSE as of March 2026. Even after EMA approval, NCPE (National Centre for Pharmacoeconomics) reimbursement assessment will be required. Memory clinic capacity โ already stretched with 12โ18 month waiting times โ will be a bottleneck for eligibility assessment (requires early diagnosis + amyloid confirmation by PET or CSF).
The Lancet 2024 Commission specifically highlights advances in fluid biomarkers for blood-based detection of Alzheimer's disease as one of the most significant recent developments. Blood biomarker testing (particularly plasma p-tau217) is becoming routine in research settings and may enter Irish memory clinics within 5 years. Lancet 2024 on biomarkers โ
Beyond the current drug pipeline, a broader revolution in neuroscience is underway. These approaches are earlier-stage โ some could prove transformative, others will fail. We present them honestly: promising but uncertain. Confidence levels are based on stage of evidence, not optimism. This is what scientific progress actually looks like.
Most scientists believe a complete cure โ restoring lost memories โ is unlikely in the next 25 years. The more realistic and impactful goal is delay and prevention: pushing back onset by 5โ10 years for most people would halve the number of people living with severe dementia at any one time.
Almost all drug pipeline activity focuses on Alzheimer's. Lewy body, vascular, and frontotemporal dementia โ affecting 30โ40% of all patients โ have no disease-modifying treatments in advanced trials. This is a major gap in global research investment.
It is possible but uncertain: GLP-1 drugs approved for Alzheimer's prevention; population blood screening programmes; gene therapy trials for APOE4 carriers.
It remains unlikely by 2040: a cure; reversal of established cognitive decline; effective treatment for later-stage dementia.
While we wait for the next generation of treatments, there is a substantial amount that can be done today to improve outcomes, quality of life, and delay progression โ for both people living with dementia and those who care for them. The Lancet 2024 Commission provides extensive evidence-based guidance on interventions. Lancet 2024 full text โ
- Refer early to memory assessment services โ earlier diagnosis unlocks post-diagnostic support, legal planning, and access to clinical trials; the new anti-amyloid drugs require early-stage disease
- Screen and aggressively treat vascular risk โ hypertension, diabetes, high LDL cholesterol, and atrial fibrillation are all modifiable now, and all reduce dementia risk (Lancet 2024)
- Prescribe hearing aids โ hearing loss is the single largest modifiable risk factor; correction may meaningfully slow cognitive decline
- Review polypharmacy carefully โ anticholinergic medications significantly increase dementia risk; structured annual review in patients over 65 is recommended
- Provide post-diagnostic planning โ advance care directives, driving assessment, capacity assessment, medication review
- Refer carers โ carer stress, depression and burnout are themselves health risks; ASI provides free support for carers
- Use HSE home support hours โ contact your GP or public health nurse; day centres and overnight respite are available through HSE
- Use structured daily routines โ predictability and familiarity significantly reduce agitation, anxiety, and challenging behaviour
- Dementia-proof the home โ door alarms, stove guards, grab rails, good lighting; OT assessment via GP referral
- Engage with the Alzheimer Society of Ireland โ free home visits, carer support groups, helpline 1800 341 341 (7 days a week, free of charge)
- Plan legal and financial matters early โ Enduring Power of Attorney must be established while the person still has legal capacity; do not delay. Citizens Information guide โ
- Use GPS tracking โ discreet wearable trackers (AngelSense, Mindme) prevent dangerous wandering incidents; among highest-impact low-cost interventions
- Stay physically active โ regular walking is the most evidence-backed activity to slow cognitive decline; aim for 30 minutes most days
- Stay socially connected โ social isolation is the 6th largest modifiable risk factor (Lancet 2024); Alzheimer cafรฉs and community groups make a real difference
- Engage in Cognitive Stimulation Therapy (CST) โ structured group programmes with randomised trial evidence for meaningful benefit CST Programme โ
- Manage vascular risk factors โ blood pressure medication, stopping smoking, controlling diabetes all protect the brain directly
- Pursue meaningful activity โ music, arts, gardening, and familiar hobbies preserve identity and wellbeing throughout the condition
- Document your wishes now โ while you have capacity, record care preferences and financial wishes for future reference
- Expand memory assessment services urgently โ waiting times of 12โ18 months are common in Ireland; anti-amyloid drug eligibility requires early diagnosis, making this bottleneck critical
- Train all healthcare staff โ basic dementia awareness training should be mandatory; specialist dementia nurses should be present in every CHO area
- Implement the National Dementia Registry โ the Minister for Health announced commencement of the registry in May 2025; full implementation is overdue
- Fund community supports โ homecare hours, day centres, and carer respite are more cost-effective than residential care (Connolly 2014)
- Prepare NCPE reimbursement pathways now โ EMA approval of lecanemab/donanemab is expected; HSE and NCPE need decision frameworks ready before approval
- Invest in prevention infrastructure โ population-level hearing screening and cardiovascular programmes deliver long-term returns
Key contact for Kilkenny & South East: HSE Community Healthcare โ Carlow Kilkenny Dementia Advisor service provides free, personalised guidance for people with dementia and their carers. Contact through your GP or directly via HSE South East. National helpline: 1800 341 341 (Alzheimer Society of Ireland โ free, 7 days a week, 9amโ5pm).
This dashboard is for informational and awareness purposes only. All population figures are estimates unless otherwise stated. Clinical decisions should always be based on individual assessment, current national guidelines (HSE, NICE), and professional judgement. Data as of March 2026.
Each term links to a reliable external source โ primarily Alzheimer Europe, WHO, the Lancet, or NHS/HSE โ so readers can explore further. Terms are listed alphabetically.
Where do the Irish numbers come from?
All case estimates, age-specific rates, gender breakdowns, and county figures in this dashboard originate from European prevalence studies โ primarily the Alzheimer Europe / Eurodem consortium, which pooled data from large population studies across multiple European countries (Netherlands, France, UK, Spain, Italy, Germany). These European rates are then mathematically applied to Ireland's CSO Census 2022 population data to produce Irish estimates.
This method has been used by: the Alzheimer Society of Ireland, the HSE National Dementia Office, and Alzheimer Europe itself when reporting Irish figures. It is the best available method โ but it is not the same as directly measuring dementia in Ireland.
Known limitations:
- Ireland's rates may differ from European averages due to population structure, lifestyle factors, and healthcare access
- The peer-reviewed range for total Irish cases is 39,272โ65,266 depending on which European dataset is applied (Cahill et al. 2019)
- No county-level Irish survey has ever been conducted
- The last comprehensive Irish-focused prevalence analysis was published in 2019
Cahill et al. 2019 โ Irish Journal of Psychological Medicine (PubMed) โ
| Data Point | Value Used | Type | Primary Source |
|---|---|---|---|
| Total Irish cases 2025 | ~64,000 | ESTIMATE | Alzheimer Society of Ireland 2025 โ |
| New cases per year | 11,000 | VERIFIED | Alzheimer Society of Ireland โ |
| Ireland 2050 projection | 141,200 | VERIFIED | Alzheimer Europe 2020 ยท Irish Times Feb 2020 โ |
| Ireland 2045 projection | 150,000+ | VERIFIED | Alzheimer Society of Ireland (different base year) โ |
| Annual economic cost | โฌ1.69bn (2010) | VERIFIED | Connolly et al. 2014, NUI Galway (PubMed) โ |
| Informal care share | 48% | VERIFIED | Connolly et al. 2014 (PubMed) โ |
| 14 modifiable risk factors | 45% PAF | VERIFIED | Lancet Commission 2024 โ Livingston et al. DOI: 10.1016/S0140-6736(24)01296-0 โ |
| Europe total cases 2025 | 12.1 million | VERIFIED | Alzheimer Europe 2025 โ |
| Europe total cases 2050 | 19.9 million | VERIFIED | Alzheimer Europe 2025 โ |
| Lecanemab FDA approval | July 2023 | VERIFIED | FDA.gov โ |
| Lecanemab efficacy | 27% slowing | VERIFIED | van Dyck et al. NEJM 2023 โ |
| Donanemab FDA approval | July 2024 | VERIFIED | FDA.gov โ |
| Donanemab efficacy | 35% slowing | VERIFIED | Sims et al. JAMA 2023 โ |
| County-level case estimates | All counties | MODELLED | National average rate applied to CSO Census 2022 population. No county-specific survey exists. Cahill et al. 2019 (limitation noted) โ |
| Age-specific prevalence rates | 0.5%โ37.5% | MODELLED | Alzheimer Europe / Eurodem consortium age-band rates applied to CSO 2022 data. Alzheimer Europe โ |
| Historical trend 2000โ2020 | 26kโ61k | MODELLED | Alzheimer Europe successive annual estimates, aligned with ASI baseline figures. |
| Prevention calculator results | Variable | MODEL ONLY | Illustrative tool using Lancet 2024 PAF values. Not a validated clinical instrument. Lancet 2024 โ |
| Reference | Link |
|---|---|
| Livingston G et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 404(10452):572โ628. | Open access โ |
| Connolly S, Gillespie P, O'Shea E, Cahill S, Pierce M. (2014). Estimating the economic and social costs of dementia in Ireland. Dementia. 13(1):5โ22. | PubMed โ |
| Cahill S, Pierce M, Werner P, Darley A, Bobersky A. (2019). Estimates of the prevalence, incidence and severity of dementia in Ireland. Irish Journal of Psychological Medicine. 36(2):129โ137. | PubMed โ |
| van Dyck CH et al. (2023). Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 388:9โ21. | NEJM โ |
| Sims JR et al. (2023). Donanemab in Early Symptomatic Alzheimer's Disease. JAMA. 330(6):512โ527. | JAMA โ |
| Alzheimer Europe (2025). Prevalence of dementia in Europe โ 2025 update. Using UN World Population Prospects 2024 data. | Alzheimer Europe โ |
| Alzheimer Europe (2020). Ireland projection to 2050: 141,200 cases. Reported in Irish Times, February 2020. | Irish Times โ |
| HSE National Dementia Office. Dementia Pathways โ clinical guidelines and referral pathways for Ireland. | HSE โ |
| Alzheimer Society of Ireland. Facts and Figures. Core statistics for dementia in Ireland. | alzheimer.ie โ |
| NICE Guideline NG97. Dementia: assessment, management and support for people living with dementia and their carers. Updated 2023. | NICE โ |
40% of dementia carers develop clinical depression. Burnout is a medical condition โ not weakness. Taking care of yourself is taking care of the person with dementia. These tools are built for you.
If they go missing: Search 15 minutes maximum then call 999 immediately. Do NOT wait 24 hours. Contact Alzheimer Society Ireland: 1800 341 341. Share recent photo, GPS tracker ID, clothing description.
If they become aggressive: Stay calm. Identify triggers โ pain, UTI, fear. Give space, never corner. Redirect gently. Document for medical team โ sudden aggression almost always has a physical cause.
If they have a fall: Do not immediately lift them. Check for pain or inability to move limbs. Keep them warm and calm. If any head contact โ call 999.
Key Ireland Numbers:
Alzheimer Society Ireland Helpline: 1800 341 341
HSE Carers Support: 1800 24 1850
Emergency: 999 / 112
Samaritans (carers in crisis): 116 123
Not everyone progresses through all stages in a straight line. Some stages overlap. Some people plateau. The pace varies enormously โ from 3 to 20 years total duration. These stages describe the general pattern, not a fixed timeline.
Important: This is an educational tool only. A score here cannot diagnose or exclude dementia. Many factors affect performance โ anxiety, fatigue, education level, language. Only a qualified clinician can make a diagnosis using validated tools in a proper clinical setting.
The brain illustration shows the six main regions affected by Alzheimer's disease โ each coloured differently. The pulsing red circles mark the hippocampus โ the first region damaged, responsible for forming new memories. Click any region to learn what it does and how Alzheimer's affects it.
This symptom checker is for educational purposes only. If you are concerned about someone's memory or behaviour, please contact your GP as the first step. Early assessment is always worthwhile.
| Benefit | Who It Is For | Amount / Details |
|---|---|---|
| Carer's Allowance | Full-time family carers | Up to โฌ248/week ยท Means tested ยท Apply to DSP |
| Carer's Benefit | Employees leaving work to care | โฌ249/week ยท Up to 2 years ยท PRSI based |
| Carer's Support Grant | All carers | โฌ1,850 per year ยท Paid annually in June |
| Disability Allowance | Person with dementia under 66 | Up to โฌ232/week ยท Means tested |
| State Pension | Person with dementia over 66 | Up to โฌ277/week ยท Contributory or Non-contributory |
| Medical Card | Low income / over 70s | Free GP, hospital, prescriptions ยท Apply to HSE |
| Fair Deal Scheme | Nursing home care | 80% of income + 7.5% assets per year ยท HSE scheme |
| Home Care Package | Living at home with support | Free HSE home care hours ยท Apply via GP/public health nurse |
| Respite Care Grant | Family carers | โฌ1,850/year to fund a break from caring |
Many families miss out on thousands of euros in entitlements because they do not know they exist. Contact Citizens Information (0818 07 4000) or the Alzheimer Society helpline to check what you are entitled to.
Mixed dementia โ most commonly Alzheimer's combined with vascular pathology โ is found at autopsy in up to 50% of dementia cases. Many patients receive a single diagnosis that understates the true complexity. Use the sidebar to explore each type in full clinical depth.
| Type | Prevalence | Typical Onset | First Symptom | Reversible? | Primary Prevention |
|---|---|---|---|---|---|
| ๐ง Alzheimer's Disease | 60โ80% | Usually 65+ | Memory loss | No | Exercise ยท BP control ยท Hearing aids |
| ๐ซ Vascular Dementia | 10โ15% | 60โ75 | Sudden cognitive drop / stroke | Partially | BP control ยท Treat AF ยท Statins |
| ๐๏ธ Lewy Body Dementia | 5โ10% | 70โ85 | Visual hallucinations ยท RBD | No | โ ๏ธ Avoid antipsychotics |
| ๐ญ Frontotemporal (FTD) | 5% | 45โ65 (young) | Personality / behaviour change | No | Genetic counselling |
| ๐ง Normal Pressure Hydrocephalus | ~5% | 60โ80 | Gait disturbance (triad) | YES โ if treated | LP tap test ยท VP shunt surgery |
| ๐ CTE | Unknown | Decades after exposure | Mood / behaviour change | No โ but preventable | Eliminate head impacts |
Click any row above โ or use the sidebar โ to read the full clinical picture for each dementia type including symptoms, prevention evidence, and treatments.
Caused by two abnormal protein deposits: amyloid-beta plaques forming between neurons and tau tangles forming inside neurons. Together they disrupt synaptic communication, trigger neuroinflammation, and cause neuronal death โ beginning in the hippocampus and entorhinal cortex 15โ20 years before any symptom appears.
Key biomarkers: Amyloid-ฮฒ42 (CSF/PET) ยท p-Tau217 blood test (90%+ accuracy) ยท APOE ฮต4 gene (increases risk 3โ12ร)
- ๐ Repetitive questioning โ each answer is forgotten immediately
- ๐ Disorientation to time, date, year, or even decade
- ๐ฌ Word-finding difficulty (anomia) โ pausing, using wrong words
- ๐บ๏ธ Getting lost in familiar places โ spatial map dissolves
- ๐ฐ Financial management failure โ bills, susceptibility to scams
- ๐ช Anosognosia โ up to 80% unaware of their own deficits
- ๐ Sundowning โ increased confusion in late afternoon and evening
| Drug | Class | Stage | Effect | Notes |
|---|---|---|---|---|
| Donepezil (Aricept) | AChE inhibitor | MildโSevere | Symptomatic โ 6โ24 months benefit | Most prescribed Alzheimer's drug worldwide since 1996 |
| Rivastigmine (Exelon) | AChE + BuChE inhibitor | MildโModerate | Patch formulation reduces GI side effects | Also approved for Parkinson's Disease Dementia |
| Memantine (Ebixa) | NMDA antagonist | ModerateโSevere | Reduces glutamate excitotoxicity | Often combined with donepezil in moderateโsevere stages |
| Lecanemab (Leqembi) | Anti-amyloid mAb | Early / MCI only | 27% slowing of clinical decline (18 months) | FDA approved July 2023. IV infusion every 2 weeks. ARIA risk. |
| Donanemab (Kisunla) | Anti-amyloid mAb | Early / MCI only | 35% slowing in tau-low patients | FDA approved 2024. May discontinue once amyloid is cleared. |
Key insight: Alzheimer's begins 15โ20 years before any symptom appears. By diagnosis, the brain has been fighting this disease silently for nearly two decades. Blood-based p-tau217 screening at GP level could soon enable detection in the silent phase โ when disease-modifying treatment is most powerful.
Caused by brain damage from strokes, TIAs, or small vessel disease โ white matter lesions and lacunar infarcts. Unlike Alzheimer's, decline is often stepwise: stable periods punctuated by sudden drops after vascular events. Executive dysfunction and gait problems frequently precede memory loss โ the key distinguishing feature from Alzheimer's. What protects the heart protects the brain.
- โก Sudden cognitive decline after stroke โ stepwise, not gradual like AD
- ๐ฏ Executive dysfunction first โ planning fails before memory loss
- ๐ถ Gait disturbance โ often the first sign of small vessel disease
- ๐ Apathy and depression โ more severe and prominent than in AD
- ๐ Fluctuating cognition โ good days and bad days
- ๐ค Emotional lability โ crying or laughing disproportionately (pseudobulbar affect)
Key insight: Vascular dementia is the most preventable dementia. Blood pressure medications, anticoagulants for AF, statins, and smoking cessation can dramatically reduce its occurrence. A person who controls blood pressure, treats AF, stops smoking, and exercises regularly may prevent the majority of their vascular dementia risk entirely.
CRITICAL SAFETY WARNING: Conventional antipsychotics โ haloperidol, risperidone, olanzapine โ can cause severe, sometimes fatal neuroleptic sensitivity reactions in Lewy Body Dementia. If a patient has visual hallucinations + fluctuating cognition + Parkinsonism โ assume LBD and never administer conventional antipsychotics. Every LBD patient should carry a MedicAlert card. This single rule saves lives.
Caused by alpha-synuclein protein aggregating into Lewy body inclusions inside neurons. Forms a spectrum with Parkinson's Disease Dementia (PDD) โ in DLB, cognitive symptoms appear first or simultaneously with motor symptoms; in PDD, motor symptoms precede dementia by more than one year. Both share identical Lewy body pathology.
- ๐ป Vivid visual hallucinations โ detailed people, animals, objects. Present in 80% of DLB. Defining feature.
- ๐ Fluctuating cognition โ alert one hour, profoundly confused the next
- ๐ถ Parkinsonism โ rigidity, bradykinesia, shuffling gait
- ๐ด REM Sleep Behaviour Disorder (RBD) โ acting out dreams. Often the FIRST sign, 10โ15 years before dementia diagnosis
- โฌ๏ธ Severe autonomic dysfunction โ fainting, constipation, urinary urgency
- โ ๏ธ Antipsychotic hypersensitivity โ potentially fatal
| Drug | Use | Effect | Notes |
|---|---|---|---|
| Rivastigmine (Exelon) | Cognition + hallucinations | Best evidence in LBD | Only drug with Level A evidence specifically in DLB |
| Quetiapine (low dose) | Hallucinations only | Most tolerated atypical antipsychotic | Use with caution โ avoid conventional antipsychotics entirely |
| Pimavanserin (Nuplazid) | Psychosis / hallucinations | No motor worsening | FDA approved 2016 for Parkinson's psychosis โ used off-label in LBD |
| Levodopa | Motor / Parkinsonism | Less effective than in Parkinson's disease | Start low โ may worsen hallucinations in some patients |
| Melatonin / Clonazepam | REM Sleep Behaviour Disorder | Reduces RBD symptoms and injury risk | Melatonin preferred in elderly โ lower fall risk than clonazepam |
Neurodegeneration of frontal and temporal lobes โ the regions controlling personality, behaviour, judgment, and speech. NOT primarily a memory disease in early stages โ this leads to frequent misdiagnosis as depression, bipolar disorder, or OCD. Three variants: behavioural (bvFTD โ personality/behaviour), Progressive Nonfluent Aphasia (PNFA โ speech production), and Semantic Dementia (SD โ loss of word meanings).
60% of FTD cases have a known genetic mutation: C9orf72 (most common), MAPT (tau protein), or GRN (progranulin). First-degree relatives should consider genetic counselling and testing.
- ๐ Disinhibition โ inappropriate remarks, shoplifting without remorse, loss of social filters
- ๐ถ Profound apathy โ complete loss of motivation; no distress about inaction
- ๐ Compulsive repetitive behaviours โ rigid routines, hoarding, tapping; mistaken for OCD
- ๐ Dietary changes โ sudden craving for sweets, gorging on food
- ๐ Loss of empathy โ cannot feel others' pain; appears callous or psychopathic to family
- ๐ฃ๏ธ Language collapse โ PNFA: effortful speech; SD: loss of word meanings ("what is a penguin?")
- โ Memory relatively preserved early โ the main reason for missed diagnosis
| Drug / Intervention | Use | Effect | Notes |
|---|---|---|---|
| SSRIs (sertraline, fluvoxamine) | bvFTD โ behavioural symptoms | Reduce disinhibition, compulsions, and aggression | First-line for bvFTD behavioural management |
| Trazodone | Sleep + agitation | Improves sleep and reduces agitation | Better evidence in FTD than in Alzheimer's disease |
| Speech & Language Therapy | Language variants (PNFA, SD) | Augmentative communication โ prolongs function | High-tech AAC devices can maintain communication for years longer |
| ASOs โ Antisense Oligonucleotides | GRN-related FTD | Targeting progranulin deficiency โ Phase II trial | First disease-specific therapy approaching clinical use for FTD |
Key insight: FTD steals the personality before it steals the memory. Families watch their loved one become socially inappropriate, emotionally hollow, and impulsive โ while still able to tell you what they had for breakfast. Correct diagnosis prevents years of harmful psychiatric medications and connects patients to appropriate trials while still eligible.
Caused by excess cerebrospinal fluid (CSF) accumulating in brain ventricles โ compressing surrounding white matter. The classic triad appears in order: (1) gait disturbance first โ the "magnetic gait" where feet appear stuck to the floor; (2) urinary incontinence second; (3) cognitive decline third. VP shunt surgery can dramatically reverse or halt decline โ often within days of the procedure.
Diagnosis: Large-volume lumbar puncture โ remove 30โ50ml CSF. If walking improves within hours, NPH is confirmed and VP shunt surgery is indicated. Both diagnostic and immediately therapeutic.
The gait in NPH is clinically distinctive: wide-based, shuffling, slow โ feet appear literally "stuck" or "magnetic" to the floor. It resembles Parkinson's disease but appears before cognitive symptoms in 70% of NPH cases. The shuffling gait is the most important clinical clue and the first symptom to look for.
Never attribute the triad of gait disturbance + urinary incontinence + cognitive change to "just aging." This combination in any older person warrants neurological evaluation and brain MRI to check ventricular size. Every missed NPH case is a preventable tragedy โ the treatment works.
| Intervention | Purpose | Effect | Notes |
|---|---|---|---|
| Large-volume lumbar puncture | Diagnosis + temporary relief | Gait improvement within hours confirms NPH | Removes 30โ50ml CSF โ "tap test" predicts shunt response |
| VP shunt (programmable valve) | Definitive surgical treatment | 70โ80% show significant improvement in gait and bladder | Programmable valve allows non-invasive pressure adjustment post-surgery |
| Physiotherapy | Post-surgery rehabilitation | Maximises gait improvement after shunt | Early post-operative rehabilitation is critical for best functional outcomes |
Key insight: NPH is one of medicine's great tragedies when missed and great triumphs when caught. A person shuffling, falling, losing bladder control, and slowly losing their mind โ told "that is just aging" โ can walk out of hospital with a spring in their step days after VP shunt surgery. Every unexplained gait disturbance in an older person deserves a brain MRI.
CTE is the first dementia we know with certainty how to prevent: stop hitting people in the head repeatedly. It is caused by human choices in sport design, rules, and culture โ not by genetics or aging. The consequences appear 20โ30 years after exposure, making cause and effect invisible to individuals making these decisions in youth. League and federation rule changes are the most powerful medical intervention available.
Caused by repeated head impacts โ not necessarily concussions, but the thousands of subconcussive hits that never cause immediate symptoms but cumulatively destroy the brain. The tau pathology resembles Alzheimer's but distributes differently: perivascularly in the depths of sulci (cortical folds) rather than spreading from the hippocampus outward. Currently can only be definitively confirmed at autopsy.
- ๐ Mood first (30sโ40s) โ depression, irritability, explosive anger; misdiagnosed as PTSD
- ๐ง Cognition second โ memory problems, executive dysfunction, slowed processing
- ๐ Suicidality โ dramatically elevated risk; Junior Seau, Dave Duerson
- ๐ Substance abuse โ self-medication of pain and depression
- โก Impulsivity and violence โ often directed at family members
- ๐ 10โ30 year latency โ cause and effect invisible to individuals in youth
When established Parkinson's Disease develops significant dementia โ cognitive symptoms appearing more than 1 year after motor symptom onset. Both PDD and DLB share identical alpha-synuclein Lewy body pathology. Characterised by executive dysfunction, attention failure, visuospatial problems, and hallucinations โ rather than the profound amnesia of Alzheimer's.
- ๐งฉ Executive function failure โ planning, organising, multitasking
- ๐ป Visual hallucinations โ detailed people and animals
- ๐ด REM Sleep Behaviour Disorder โ acting out dreams
- โฌ๏ธ Orthostatic hypotension โ dizziness on standing, falls
- ๐ Depression and anxiety โ present in 40โ60%
- ๐ Attention breakdown before memory loss
| Drug | Use | Notes |
|---|---|---|
| Rivastigmine (Exelon) | Cognition | FDA approved specifically for PDD 2006. 27% reduction in decline. Patch preferred. |
| Pimavanserin (Nuplazid) | Hallucinations | No motor worsening. FDA approved 2016 for Parkinson's psychosis. |
| Levodopa/Carbidopa | Motor symptoms | Gold standard for Parkinson's motor control. Does not treat cognition. |
| SSRIs (sertraline) | Depression | Avoid amitriptyline โ anticholinergic effects worsen cognition. |
Key insight: Vigorous aerobic exercise has the best evidence of any intervention for neuroprotection in Parkinson's. High-intensity treadmill training, cycling, boxing (non-contact) โ 3โ5 sessions per week. Exercise increases BDNF and may directly slow alpha-synuclein aggregation.
Young-onset dementia arrives when children still need parenting, mortgages are unpaid, and identity is bound to career. Standard older-adult services are almost entirely inappropriate for this group.
Employment: The person may still be working when symptoms begin. Colleagues notice errors before family does. Occupational health referral and reasonable adjustments can extend working life.
Financial: Mortgage protection insurance may cover dementia. Income protection policies may activate. Disability Allowance is available under 66. Contact Citizens Information: 0818 07 4000.
Children: Age-appropriate honest communication with children is vital. Young Carers Ireland (youngcarers.ie) provides specific support for children who are caring for a parent with dementia.
Mixed dementia occurs when a person has more than one type of dementia pathology simultaneously. The most common combination is Alzheimer's disease pathology (amyloid plaques and tau tangles) alongside vascular damage (white matter lesions, lacunar infarcts). This is found at autopsy in approximately 50% of all dementia cases โ meaning the single diagnosis most people receive during life understates the true complexity of what is happening in the brain.
Lewy body pathology is also commonly found alongside Alzheimer's pathology โ making the triad of AD + vascular + Lewy bodies a frequent autopsy finding in elderly dementia patients.
Korsakoff syndrome is caused by severe thiamine (Vitamin B1) deficiency โ most commonly from chronic heavy alcohol use, which both reduces thiamine intake and impairs thiamine absorption. It damages the mammillary bodies and thalamus โ structures critical for memory formation. The defining feature is confabulation: the person unconsciously invents detailed, plausible memories to fill the gaps โ they are not lying, they genuinely believe their fabricated accounts.
- ๐ณ๏ธ Severe anterograde amnesia โ cannot form any new memories
- ๐ Confabulation โ invents detailed false memories without knowing it
- ๐ Eye movement abnormalities โ nystagmus, gaze palsy
- ๐ถ Ataxia โ unsteady gait, coordination problems
- ๐ถ Apathy and flat affect โ little emotional response
- ๐ Retrograde amnesia โ gaps in memories from years before onset
Wernicke's Encephalopathy is a medical emergency that precedes Korsakoff syndrome. Classic triad: confusion + eye movement abnormalities + ataxia. If suspected, give IV thiamine (Pabrinex) immediately before any glucose โ giving glucose first without thiamine can precipitate irreversible brain damage. Every A&E should follow this protocol for alcohol-dependent patients.
Alcohol Action Ireland: 01 878 0610 ยท Drinkaware Ireland: drinkaware.ie ยท AA Ireland: aa.ie ยท HSE Drug & Alcohol Helpline: 1800 459 459
- โก Rapidly progressive dementia โ weeks not years
- ๐คธ Myoclonus โ sudden involuntary muscle jerks, often startle-triggered
- ๐๏ธ Visual disturbances and hallucinations
- ๐ถ Cerebellar ataxia โ severe coordination failure
- ๐ด Akinetic mutism in late stages โ awake but unresponsive
- ๐ง Characteristic MRI findings โ cortical ribboning, basal ganglia signal
CJD is a notifiable disease in Ireland. All suspected cases must be reported to the HPSC. There is no treatment โ care is palliative. The National CJD Research & Surveillance Unit (UK) maintains the international registry.
PCA is a syndrome โ most commonly caused by Alzheimer's pathology โ in which neurodegeneration targets the posterior brain regions (parietal, occipital, posterior temporal cortices) rather than the hippocampus first. The result is devastating: the person loses the ability to read, write, drive, navigate space, recognise objects by sight, and calculate โ while their episodic memory and verbal fluency may remain largely intact for years. It is profoundly under-diagnosed because clinicians do not expect Alzheimer's in a 57-year-old who still knows what year it is.
- ๐ Cannot read โ letters visible but uninterpretable (alexia)
- โ๏ธ Cannot write legibly โ visuomotor coordination fails (agraphia)
- ๐ Driving becomes impossible โ cannot judge distances or read signs
- ๐ช Cannot use familiar tools โ dressing apraxia
- ๐ข Arithmetic fails โ cannot read a clock face (acalculia)
- ๐ผ๏ธ Object agnosia โ cannot recognise objects by sight, only by touch
- โ Memory relatively preserved early โ the main diagnostic confusion
- ๐ฐ Severe anxiety โ living in a world that no longer makes visual sense
Key insight: PCA is Alzheimer's wearing a disguise. The patient seems too young, too articulate, and too sharp โ because they are. Any person under 65 with progressive visuospatial decline and normal episodic memory should be referred urgently to a cognitive neurologist. The diagnostic odyssey currently averages 3โ4 years โ this must be shortened.
Every person with Down syndrome has three copies of chromosome 21, which carries the APP (amyloid precursor protein) gene. This causes lifelong overproduction of amyloid-beta protein โ on average 1.5ร normal levels from birth. Amyloid plaques begin forming in the brain during adolescence โ 30+ years before any dementia symptoms. By age 40, virtually all individuals with Down syndrome have full Alzheimer's pathology on PET scan. Most develop clinical dementia between ages 50โ65. Down syndrome is therefore the most penetrant genetic model of Alzheimer's disease in the world.